Moderna Raises Full-Year Revenue Growth Outlook Following Third Quarter Earnings Beat
Moderna (MRNA) has reported third-quarter financial results that exceeded both top-line and bottom-line analyst estimates. Driven by strong performance, the biotechnology company has officially raised its full-year revenue growth guidance to a range of 15% to 25%. The earnings report comes amid significant market interest regarding Moderna's pipeline expansion beyond COVID-19, specifically focusing on breakthroughs in melanoma treatments and cancer vaccines. While valuation debates persist among investors, the company's ability to beat estimates provides a positive momentum signal for its fiscal outlook.
Tickers: $MRNA